28976989|t|Vitamin D and methylarginines in chronic kidney disease (CKD).
28976989|a|BACKGROUND: Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less than in those not receiving this drug. METHODS: In the frame of a randomized, double-blind, placebo controlled trial, the Paracalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY), we investigated whether vitamin D receptor activation by paricalcitol (2 mug/day x 12 weeks) affects the plasma concentration of ADMA and symmetric dimethyl arginine (SDMA) in 88 patients with stage 3 to 4 CKD. RESULTS: Paricalcitol produced the expected small rise in serum calcium and phosphate and a marked PTH suppression. However, ADMA [Paricalcitol: baseline 0.75 muMol/L (95%CI: 0.70-0.81), 12 week 0.72 muMol/L (95%CI: 0.66-0.78); Placebo: baseline 0.75 muMol/L (95%CI: 0.70-0.90) 12 weeks 0.70 muMol/L (95%CI: 0.66-0.74)] and SDMA [Paricalcitol: baseline 0.91 muMol/L (95%CI: 0.82-1.00), 12 week 0.94 muMol/L (95%CI: 0.82-0.1.06); Placebo: baseline 0.91 muMol/L (95%CI: 0.82-1.06) 12 weeks 0.99 muMol/L (95%CI: 0.88-1.10)] remained unchanged during the trial and 2 weeks after stopping these treatments. CONCLUSIONS: Paricalcitol does not modify plasma ADMA and SDMA in patients with stage 3-4 CKD. The apparent beneficial effects of paricalcitol on ADMA registered in cross-sectional studies is likely attributable to confounding by indication rather than to a true effect of this drug on ADMA metabolism.
28976989	0	9	Vitamin D	Chemical	MESH:D014807
28976989	14	29	methylarginines	Chemical	-
28976989	33	55	chronic kidney disease	Disease	MESH:D051436
28976989	57	60	CKD	Disease	MESH:D051436
28976989	75	84	Vitamin D	Chemical	MESH:D014807
28976989	161	173	nitric oxide	Chemical	MESH:D009569
28976989	181	209	asymmetric dimethyl arginine	Chemical	MESH:C018524
28976989	211	215	ADMA	Chemical	MESH:C018524
28976989	248	251	CKD	Disease	MESH:D051436
28976989	252	260	patients	Species	9606
28976989	278	296	vitamin D receptor	Gene	7421
28976989	307	319	paricalcitol	Chemical	MESH:C084656
28976989	337	341	ADMA	Chemical	MESH:C018524
28976989	486	498	Paracalcitol	Chemical	-
28976989	527	549	chronic kidneY disease	Disease	MESH:D051436
28976989	551	556	PENNY	Disease	MESH:D051436
28976989	583	601	vitamin D receptor	Gene	7421
28976989	616	628	paricalcitol	Chemical	MESH:C084656
28976989	688	692	ADMA	Chemical	MESH:C018524
28976989	697	724	symmetric dimethyl arginine	Chemical	MESH:C024917
28976989	726	730	SDMA	Chemical	MESH:C024917
28976989	738	746	patients	Species	9606
28976989	765	768	CKD	Disease	MESH:D051436
28976989	779	791	Paricalcitol	Chemical	MESH:C084656
28976989	834	841	calcium	Chemical	MESH:D002118
28976989	846	855	phosphate	Chemical	MESH:D010710
28976989	869	872	PTH	Gene	5741
28976989	895	899	ADMA	Chemical	MESH:C018524
28976989	901	913	Paricalcitol	Chemical	MESH:C084656
28976989	1094	1098	SDMA	Chemical	MESH:C024917
28976989	1100	1112	Paricalcitol	Chemical	MESH:C084656
28976989	1385	1397	Paricalcitol	Chemical	MESH:C084656
28976989	1421	1425	ADMA	Chemical	MESH:C018524
28976989	1430	1434	SDMA	Chemical	MESH:C024917
28976989	1438	1446	patients	Species	9606
28976989	1462	1465	CKD	Disease	MESH:D051436
28976989	1502	1514	paricalcitol	Chemical	MESH:C084656
28976989	1518	1522	ADMA	Chemical	MESH:C018524
28976989	1658	1662	ADMA	Chemical	MESH:C018524
28976989	Positive_Correlation	MESH:C084656	MESH:D010710
28976989	Association	MESH:C018524	MESH:D014807
28976989	Negative_Correlation	MESH:C084656	5741
28976989	Positive_Correlation	MESH:C084656	MESH:D002118
28976989	Positive_Correlation	MESH:C084656	7421
28976989	Negative_Correlation	MESH:C084656	MESH:D051436

